Testing NalIriFOx as first treatment for metastatic pancreatic cancer
Part of Cancer clinical trials.
This trial is testing a drug combination called NalIriFOx as the first treatment for people with pancreatic cancer that has spread. The goal is to see if it is safe and works well over the long term.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with pancreatic cancer that has spread to other parts of the body (metastatic).
- You are about to start your very first treatment for this cancer with a combination of drugs called NalIriFOx (as decided by your doctor).
- You are willing to sign a consent form saying you understand and agree to be in the study.
- You have not had chemotherapy or radiation before or after surgery in the last 6 months.
- You have never been treated with liposomal irinotecan (a drug also called Onivyde).
- You have not previously received any chemotherapy or other cancer treatment for the spread of your pancreatic cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies Nalirifox (chemotherapy) given together with radiation therapy for pancreatic ductal adenocarcinoma that has not spread to distant organs. It may help shrink the cancer and improve local control, especially when surgery is not an option right now.
This trial tests a combination of chemotherapy (NALIRI-XELOX) plus a newer immunotherapy drug (AK104) as a first treatment for people with advanced pancreatic cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatments.
This study looks at two treatment approaches for pancreatic cancer. In the first part, a new drug combo called NALIRIFOX is given as the first treatment. In the second part, researchers test whether a special antibiotic can make a common chemo work better by targeting gut bacteria.
This study tests a monthly rotation of two chemotherapy combinations (NALIRIFOX and GnP) as the first treatment for metastatic pancreatic cancer. The goal is to see if alternating the drugs helps control the cancer while reducing side effects.
This study tests whether combining three treatments—NALIRIFOX (chemotherapy), Adebrelimab (an immune-boosting antibody), and PULSAR (radiation)—can help people with advanced pancreatic cancer that hasn't been treated before. The goal is to see if this combination works better than standard care.
This trial tests a combination of chemotherapy (Nal-IRI, 5-FU, leucovorin), an immunotherapy drug (PD-L1 inhibitor), and a targeted anti-angiogenic pill, with or without radiation (SBRT), as a second-line treatment for people with metastatic pancreatic cancer that has progressed after first-line therapy.
Hear when a new Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.